Drugs / CPK850
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03374657 | Aug 2018 → May 2026 | retinitis pigmentosa | Novartis Pharmaceuticals | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPK850 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03374657 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “an adeno-associated viral vector (AAV8-RLBP1)” PMID 39256350 ↗ Sep 2024 |
| Route | Other | “administered via subretinal injection” NCT03374657 ↗ |